Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine.

Behavioural brain research 20110930

Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.

Neuroscience letters 20110815

A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.

Sleep medicine 20110501

Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.

Sleep medicine 20110501

Equine pituitary pars intermedia dysfunction.

The Veterinary clinics of North America. Equine practice 20110401

The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.

Drug safety 20110401

Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein.

Biochemical and biophysical research communications 20110318

Dopamine agonists for restless legs syndrome.

The Cochrane database of systematic reviews 20110316

Dopaminergic stimulation enhances confidence and accuracy in seeing rapidly presented words.

Journal of vision 20110223

Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.

Neuro endocrinology letters 20110101

Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.

Internal medicine (Tokyo, Japan) 20110101

[New drugs for horses and production animals in 2010].

Tierarztliche Praxis. Ausgabe G, Grosstiere/Nutztiere 20110101

Juvenile hormone synthesis is stimulated by activation of dopamine D1-like receptors in Drosophila.

Doklady. Biochemistry and biophysics 20110101

Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid.

Journal of pharmacy practice 20101201

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Bioorganic & medicinal chemistry letters 20101101

Drug-induced valvulopathy: an update.

Toxicologic pathology 20101001

Compulsive singing associated with a dopamine agonist in Parkinson disease.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 20100601

Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100501

Excessive daytime somnolence in spinocerebellar ataxia type 1.

Journal of the neurological sciences 20100315

Treatment of hyperadrenocorticism in donkeys.

The Veterinary record 20100130

Retroperitoneal fibrosis secondary to pergolide therapy.

Internal medicine (Tokyo, Japan) 20100101

Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.

Veterinary therapeutics : research in applied veterinary medicine 20100101

Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

Nature chemical biology 20091001

Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.

Biological & pharmaceutical bulletin 20091001

Drug-induced fibrotic valvular heart disease.

Lancet (London, England) 20090815

Primary gait ignition disorder: report of three cases.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20090801

Rounded atelectasis and respiratory compromise secondary to pergolide use.

Respirology (Carlton, Vic.) 20090801

The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?

Heart advisor 20090801

Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20090601

Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.

American journal of physiology. Heart and circulatory physiology 20090601

Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.

Clinical neurology and neurosurgery 20090501

Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.

Heart (British Cardiac Society) 20090401

Supports compounding standards.

Journal of the American Veterinary Medical Association 20090401

Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.

Internal medicine journal 20090401

Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.

Neuropsychologia 20090401

Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.

Journal of neurology 20090301

High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20090201

Effects of compounding and storage conditions on stability of pergolide mesylate.

Journal of the American Veterinary Medical Association 20090201

[Impulse control disorder induced by the use of dopamine agonists].

Nederlands tijdschrift voor geneeskunde 20090117

[Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].

Nederlands tijdschrift voor geneeskunde 20090117

Punding in patients on dopamine agonists for restless leg syndrome.

Movement disorders : official journal of the Movement Disorder Society 20090115

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 20090115

Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20090101

[Pleural effusion caused by pergolide].

Archivos de bronconeumologia 20090101

Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.

Journal of cardiothoracic surgery 20090101

Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome.

European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20081101

Pergolide and valvular heart disease: the lower the better?

European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20081101

Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.

Journal of neurology 20081001

A ligand-based approach to mining the chemogenomic space of drugs.

Combinatorial chemistry & high throughput screening 20080901

Pergolide increases the efficacy of cathodal direct current stimulation to reduce the amplitude of laser-evoked potentials in humans.

Journal of pain and symptom management 20080701

Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.

Journal of neurology 20080701

Rheumatoid arthritis accompanied by Parkinson disease.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20080601

The frequency of cardiac valvular regurgitation in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20080515

Pergolide associated cardiac valvulopathy based on Ontario administrative data.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080501

The variability of levodopa response in Parkinson's disease: is sensitization reversible?

Movement disorders : official journal of the Movement Disorder Society 20080430

Sclerosing mesenteritis: an ergot-related complication of pergolide therapy in Parkinson's disease?

Movement disorders : official journal of the Movement Disorder Society 20080430

Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Journal of neurochemistry 20080301

Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.

The Journal of pharmacology and experimental therapeutics 20080301

Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.

Journal of sleep research 20080301

[Isolated pulmonary hypertension and pergolide].

Revue neurologique 20080301

Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.

Journal of neuroscience research 20080215

Pergolide protects CA1 neurons from apoptosis in a gerbil model of global cerebral ischemia.

Neurological research 20080201

Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.

Journal of the American Geriatrics Society 20080201

[Low dose pergolide induced systemic edema and pleural effusion in a patient with Parkinson's disease].

Rinsho shinkeigaku = Clinical neurology 20080201

Dopaminergic potentiation of rTMS-induced motor cortex inhibition.

Biological psychiatry 20080115

Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.

The Journal of international medical research 20080101

Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.

Clinical neuropharmacology 20080101

[Cardiac valvulopathy and dopamine agonist].

Neurologia (Barcelona, Spain) 20071201

Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.

Archives of neurology 20071201

Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.

Movement disorders : official journal of the Movement Disorder Society 20071115

Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.

Psychopharmacology 20071101

Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Journal of neurology 20071101

Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 20071015

Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Neurochemical research 20071001

Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.

Clinical linguistics & phonetics 20071001

Dopamine treatment in brain-dead rats mediates anti-inflammatory effects: the role of hemodynamic stabilization and D-receptor stimulation.

Transplant international : official journal of the European Society for Organ Transplantation 20070901

In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.

European heart journal 20070901

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

The Lancet. Neurology 20070901

Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.

Journal of neurochemistry 20070801

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.

Neurology 20070703

Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20070701

FDA-CVM works to address concerns about pergolide supplies.

Journal of the American Veterinary Medical Association 20070701

Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal.

European journal of pharmacology 20070622

Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists.

European journal of neurology 20070601

Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.

Journal of neuroscience research 20070515

Reversal of cocaine sensitization-induced behavioral sensitization normalizes GAD67 and GABAA receptor alpha2 subunit expression, and PKC zeta activity.

Biochemical and biophysical research communications 20070511

Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease.

Journal of neurology, neurosurgery, and psychiatry 20070501

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.

Clinical neurology and neurosurgery 20070501

Effects of pergolide on severe sleep bruxism in a patient experiencing oral implant failure.

Journal of oral rehabilitation 20070501

Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?

Neurology 20070424

Dopamine agonists and valvular heart disease.

The New England journal of medicine 20070419

Dopamine agonists and valvular heart disease.

The New England journal of medicine 20070419

Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.

The Journal of pharmacology and experimental therapeutics 20070401

Parkinson's drugs linked to heart valve trouble.

Harvard heart letter : from Harvard Medical School 20070401

[Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].

Rinsho shinkeigaku = Clinical neurology 20070401

Improved photostability indicating ion-pair chromatography method for pergolide analysis in tablets and in the presence of cyclodextrins.

Journal of pharmaceutical and biomedical analysis 20070312

Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

Archives of neurology 20070301

Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 20070301

Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070201

Quetiapine in a case with Parkinson disease and pathological gambling.

Journal of clinical psychopharmacology 20070201

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

Progress in neuro-psychopharmacology & biological psychiatry 20070130

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.

Movement disorders : official journal of the Movement Disorder Society 20070115

Drugs and valvular heart disease.

The New England journal of medicine 20070104

Dopamine agonists and the risk of cardiac-valve regurgitation.

The New England journal of medicine 20070104

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

The New England journal of medicine 20070104

About the anti-Parkinson equivalency of levodopa and dopamine agonists.

Clinical neuropharmacology 20070101

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Drug safety 20070101

[Dopamine agonists in the treatment of motor complications in advanced Parkinson's disease].

Neurologia i neurochirurgia polska 20070101

[Reactivity and communication of Health Authorities toward health professionals: a public health priority].

Therapie 20070101

Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: A rare case of iatrogenic paraphilia.

Progress in neuro-psychopharmacology & biological psychiatry 20061230

Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.

The international journal of neuropsychopharmacology 20061201

Tonic dopaminergic stimulation impairs associative learning in healthy subjects.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20061101

Medical hazards of the internet: gambling in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20061001

Dopaminergic modulation of semantic priming in healthy volunteers.

Biological psychiatry 20060915

Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans.

Psychopharmacology 20060901

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 20060801

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.

Clinical therapeutics 20060801

Pergolide-induced ergotism.

Neurology 20060711

Sensorimotor effects of pergolide, a dopamine agonist, in healthy subjects: a lateralized readiness potential study.

Psychopharmacology 20060701

Association of dopamine agonist use with impulse control disorders in Parkinson disease.

Archives of neurology 20060701

Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement.

Parkinsonism & related disorders 20060601

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Journal of pharmacokinetics and pharmacodynamics 20060601

Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.

Pharmacopsychiatry 20060501

A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory.

Neuroscience 20060428

[Ergoline-induced retroperitoneal fibrosis].

Ugeskrift for laeger 20060424

Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide.

Movement disorders : official journal of the Movement Disorder Society 20060401

Hiccups associated with dopamine agonists in Parkinson disease.

Neurology 20060314

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.

Movement disorders : official journal of the Movement Disorder Society 20060301

Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex.

The European journal of neuroscience 20060301

[Ergoline-induced retroperitoneal fibrosis].

Ugeskrift for laeger 20060227

PI3 kinase is involved in cocaine behavioral sensitization and its reversal with brain area specificity.

Biochemical and biophysical research communications 20060224

Cardiac valvulopathy associated with pergolide use.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20060201

Valvular heart disease in pergolide-treated Parkinson's disease.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20060201

Pergolide-associated valvular heart disease.

Comprehensive therapy 20060101

The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.

Parkinsonism & related disorders 20051201

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.

The Journal of pharmacology and experimental therapeutics 20051201

[Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].

Journal of cardiology 20051201

Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans.

Psychopharmacology 20051001

The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values.

Psychopharmacology 20051001

Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction.

Circulation 20050906

Normalization of voice in spasmodic dysphonia during transient global amnesia.

Movement disorders : official journal of the Movement Disorder Society 20050901

High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.

Parkinsonism & related disorders 20050901

Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): Pregnancy associated with daytime sleepiness and nighttime restlessness.

Sleep medicine 20050901

Reversible weight gain and prolactin levels--long-term follow-up in childhood.

Journal of pediatric endocrinology & metabolism : JPEM 20050901

Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.

Archives of neurology 20050801

Valvular heart disease in patients taking pergolide.

Mayo Clinic proceedings 20050801

[Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].

Revue neurologique 20050701

Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia.

Journal of clinical psychopharmacology 20050601

Pergolide improvement in neuroleptic-resistant Tourette cases: various mechanisms causing tics.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20050601

Levodopa in the treatment of Parkinson's disease: current controversies.

Movement disorders : official journal of the Movement Disorder Society 20050501

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Movement disorders : official journal of the Movement Disorder Society 20050501

Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.

Neurology 20050426

[Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].

Nederlands tijdschrift voor geneeskunde 20050416

Diagnosis and management of pergolide-induced fibrosis.

Movement disorders : official journal of the Movement Disorder Society 20050401

Differential dopaminergic modulation of executive control in healthy subjects.

Psychopharmacology 20050401

[Optimum dosage of pergolide in patients with Parkinson's disease].

Rinsho shinkeigaku = Clinical neurology 20050401

Trial of subtherapeutic pergolide in de novo Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20050301

Sleep attacks in patients receiving dopamine-receptor agonists.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050301

Pergolide effect on cognitive functions in early-mild Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20050201

Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.

Behavioural brain research 20050130

A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.

European journal of neurology 20050101

[Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].

Casopis lekaru ceskych 20050101

Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

Clinical neuropharmacology 20050101

High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.

Archives of gerontology and geriatrics 20050101

Use of dopamine agonist pergolide in outpatient treatment of cocaine dependence.

Substance use & misuse 20050101

Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro.

Clinical neuropharmacology 20050101

Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study.

American journal of therapeutics 20050101

Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease.

Clinical neuropharmacology 20050101

Reversible Pisa syndrome in Parkinson's disease during treatment with pergolide: a case report.

Clinical neuropharmacology 20050101

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

Pharmacological reports : PR 20050101

Pharmacologic resistance in prolactinoma patients.

Pituitary 20050101

Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Pituitary 20050101

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.

Movement disorders : official journal of the Movement Disorder Society 20041201

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.

Movement disorders : official journal of the Movement Disorder Society 20041201

Dopaminagonists and fibrotic valvular heart disease: further considerations.

Movement disorders : official journal of the Movement Disorder Society 20041201

Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells.

Neurochemical research 20041201

[Special issue: the reports presented during the 5th Parkinson's Physicians' Symposium].

Praxis 20041103

[Are there innovations in the treatment of Parkinson's disease?].

Praxis 20041103

Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.

Movement disorders : official journal of the Movement Disorder Society 20041101

Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.

The Netherlands journal of medicine 20041101

Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

The Cochrane database of systematic reviews 20041018

Cardiopulmonary complications of ergot-derivative dopamine agonists.

The Journal of clinical psychiatry 20041001

Evidence for a differential medial prefrontal dopamine D1 and D2 receptor regulation of local and ventral tegmental glutamate and GABA release: a dual probe microdialysis study in the awake rat.

Brain research 20040813

Equine cushing-like syndrome: diagnosis and therapy in two cases.

Veterinary research communications 20040801

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.

Neurology 20040727

Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.

European journal of neurology 20040701

Pergolide in Parkinson's disease: time for a change?

Lancet (London, England) 20040605

Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20040601

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.

Movement disorders : official journal of the Movement Disorder Society 20040601

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 20040601

Diagnosis and management of pergolide-induced fibrosis.

Movement disorders : official journal of the Movement Disorder Society 20040601

Extensive fibromuscular dysplasia in a patient with Parkinson disease.

The American journal of the medical sciences 20040601

Rapid onset of pergolide-induced pulmonary fibrosis in a patient with corticobasal degeneration.

Hospital medicine (London, England : 1998) 20040601

A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation.

Biochemical pharmacology 20040501

Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.

Neurology 20040427

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Lancet (London, England) 20040410

Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.

Parkinsonism & related disorders 20040301

Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.

Archives of neurology 20040101

[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20040101

[Pergolide treatment and cardiac valve pathology: the continuing saga of ergotamine-induced fibrosis].

Revue neurologique 20040101

Pergolide, terguride and N,N'-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery.

Physiological research 20040101

Plasma homocysteine levels in pergolide-treated Parkinson disease patients.

Clinical neuropharmacology 20040101

Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients.

Polish journal of pharmacology 20040101

Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease.

Clinical neuropharmacology 20040101

Valvular health disease with pergolide.

Prescrire international 20031201

The pharmacokinetics of pergolide in Parkinson's disease.

Current opinion in neurology 20031201

Comparing dopamine agonists in Parkinson's disease.

Current opinion in neurology 20031201

Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease.

Current opinion in neurology 20031201

Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.

Movement disorders : official journal of the Movement Disorder Society 20031101

[Effects of D1 and D2 dopamine receptor agonists and antagonists on cerebral ischemia/reperfusion injury].

Sheng li xue bao : [Acta physiologica Sinica] 20031025

L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.

Neurology 20031014

Pergolide mesylate form II.

Acta crystallographica. Section C, Crystal structure communications 20031001

Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.

Neurology 20030923

[Tardive dyskinesia: pergolid, a possible therapeutic option].

Psychiatrische Praxis 20030901

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.

Neurology 20030812

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

European journal of neurology 20030701

High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities.

Journal of mass spectrometry : JMS 20030701

Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.

Life sciences 20030620

Dopamine agonist therapy for hyperprolactinemia.

Clinical obstetrics and gynecology 20030601

Additional insights into pergolide-associated valvular heart disease.

Mayo Clinic proceedings 20030601

The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.

Mayo Clinic proceedings 20030601

[Hypersexuality during use of levodopa].

Nederlands tijdschrift voor geneeskunde 20030517

The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.

Age and ageing 20030501

[Gilles de la tourette syndrome: clinical spectrum and management].

Revista de neurologia 20030401

Neuroendocrine and behavioral responses to dopaminergic agonists in adolescents with alcohol abuse.

Psychopharmacology 20030301

[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry 20030301

The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.

Journal of psychopharmacology (Oxford, England) 20030301

Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep.

Sleep medicine 20030301

Tic reduction with pergolide in a randomized controlled trial in children.

Neurology 20030225

Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20030201

The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action.

Journal of controlled release : official journal of the Controlled Release Society 20030109

Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20030101

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

Experimental neurology 20030101

Cognitive effects of the dopamine receptor agonist pergolide.

Neuropsychologia 20030101

Hyperprolactinemia: pathophysiology and management.

Treatments in endocrinology 20030101

Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.

Parkinsonism & related disorders 20021201

Drug-related valvular heart disease: here we go again: will we do better this time?

Mayo Clinic proceedings 20021201

Valvular heart disease in patients taking pergolide.

Mayo Clinic proceedings 20021201

Dopamine agonist monotherapy in Parkinson's disease.

Lancet (London, England) 20021130

Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry 20021101

Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.

Equine veterinary journal 20021101

Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice.

The Journal of pharmacology and experimental therapeutics 20021001

[Cutaneous vasculitis during pergolide mesylate treatment].

La Revue de medecine interne 20020901

The effect of pergolide on cognitive performance of young and middle-aged rats.

The International journal of neuroscience 20020901

[Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].

Rinsho shinkeigaku = Clinical neurology 20020801

Pituitary pars intermedia dysfunction: equine Cushing's disease.

The Veterinary clinics of North America. Equine practice 20020801

Transdermal delivery of pergolide from surfactant-based elastic and rigid vesicles: characterization and in vitro transport studies.

Pharmaceutical research 20020701

Pergolide-induced lung disease in patients with Parkinson's disease.

Respiratory medicine 20020701

[Pergolide: a useful agonist for the treatment of Parkinson disease].

Revue neurologique 20020701

Dopamine receptor agonists for treating prolactinomas.

Expert opinion on investigational drugs 20020601

Delayed visual loss following pergolide treatment of a prolactinoma.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20020601

[Multiple latency test in a patient with episodes of sleep induced by pergolide].

Revista de neurologia 20020601

Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist.

Neuroreport 20020507

Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.

Psychopharmacology 20020501

Pergolide protects dopaminergic neurons in primary culture under stress conditions.

Journal of neural transmission (Vienna, Austria : 1996) 20020501

A new design of a polysomnography-based multi-center treatment study for the restless legs syndrome.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 20020401

[The evolution of use of anti-Parkinson drugs in Spain].

Revista de neurologia 20020401

Antiparkinsonian treatment in pregnancy.

Movement disorders : official journal of the Movement Disorder Society 20020301

[Multiple system atrophy which had been treated as juvenile Parkinson's disease].

No to shinkei = Brain and nerve 20020301

Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD.

Neurology 20020212

Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2).

European journal of pharmacology 20020102

Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.

The Journal of pharmacology and experimental therapeutics 20020101

Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide.

Postgraduate medical journal 20020101

Pergolide in the treatment of patients with early and advanced Parkinson's disease.

Clinical neuropharmacology 20020101

Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease.

Journal of neurology 20020101

Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension.

Blood pressure 20020101

Elastic vesicles: interaction with human skin and drug transport.

Cellular & molecular biology letters 20020101

DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20020101

DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 20020101

[Use of dopamine agonists in the treatment of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20020101

Pergolide-induced pleuropulmonary fibrosis.

Clinical neuropharmacology 20020101

Pergolide mesilate may improve fatigue in patients with Parkinson's disease.

Behavioural neurology 20020101

Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).

Journal of veterinary internal medicine 20020101

Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.

Pituitary 20020101

Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1.

European journal of pharmacology 20011214

Effects of pergolide on sensorimotor gating of the startle reflex in rats.

Psychopharmacology 20011101

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.

Movement disorders : official journal of the Movement Disorder Society 20010901

Pleuropulmonary disease due to pergolide use for restless legs syndrome.

Chest 20010701

Long-term effects of pergolide in the treatment of restless legs syndrome.

Neurology 20010522

[Parkinson's disease].

Presse medicale (Paris, France : 1983) 20010303

[Sleep attacks and pergolide mesylate].

Neurologia (Barcelona, Spain) 20010201

Efficacy and tolerability of dopamine agonists in a parkinsonian population.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20010201

Switching from pergolide to pramipexole in patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) 20010101

Adverse outcomes in a controlled trial of pergolide for cocaine dependence.

Journal of addictive diseases 20010101

Quick titration of pergolide in cotreatment with domperidone is safe and effective.

Clinical neuropharmacology 20010101

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Drugs & aging 20010101

The effect of a dopamine agonist on dysarthric speech production: a case study.

Journal of communication disorders 20010101

Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.

PharmacoEconomics 20010101

Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20010101

Chronic akinetic mutism after mesencephalic-diencephalic infarction: remediated with dopaminergic medications.

Neurorehabilitation and neural repair 20010101

[Dopaminergic agonists in the treatment of Parkinson's disease].

Revue medicale de Bruxelles 20001201

A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence.

Drug and alcohol dependence 20000801

Transverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen.

Sleep 20000801

Sleep attacks (sleep episodes) with pergolide.

Lancet (London, England) 20000415

Sleep attacks and Parkinson's disease treatment.

Lancet (London, England) 20000415

Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.

Pharmacotherapy 19991201

Effect of pergolide on restless legs and leg movements in sleep in uremic patients.

Sleep 19980915

Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society 19980501

Cenesthetic hallucinations in a patient with Parkinson's disease.

Journal of neurology, neurosurgery, and psychiatry 19970701

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Journal of neural transmission (Vienna, Austria : 1996) 19970101

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.

Movement disorders : official journal of the Movement Disorder Society 19960501

A 'combined' levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.

Movement disorders : official journal of the Movement Disorder Society 19950901

Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.

Endocrine regulations 19920301

Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.

Annals of neurology 19910801

Hallucinations and confusion after pergolide withdrawal.

Clinical neuropharmacology 19881201

Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.

The Journal of pharmacology and experimental therapeutics 19851201

The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.

The American journal of the medical sciences 19850901

Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.

Neurology 19850501

Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions.

European journal of pharmacology 19840713

Erythromelalgia following pergolide administration.

The British journal of dermatology 19840701

Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.

The Journal of pharmacology and experimental therapeutics 19840301

Dopa dose-dependent sexual deviation.

The British journal of psychiatry : the journal of mental science 19830301

Anwesenheit: psychopathology and clinical associations.

The British journal of psychiatry : the journal of mental science 19821201